The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2020 Jun 20

PMID 32556892

Citations 53

Authors

Juan Simon Rico-Mesa

Daniel Rosas

Ashkan Ahmadian-Tehrani

Averi White

Allen S Anderson

Robert Chilton

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature.

Recent Findings: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.

Citing Articles

COVID-19 Increases the Risk of New Myocardial Infarction in Patients with Old Myocardial Infarction: A Retrospective Observational Study.

El-Menyar A, Ramzee A, Asim M, Shahid F, Ata Y, El Baba H Clin Med Insights Cardiol. 2024; 18:11795468241301133.

PMID: 39697349 PMC: 11653445. DOI: 10.1177/11795468241301133.

The Role and Implications of COVID-19 in Incident and Prevalent Heart Failure.

Rico-Mesa J, Haloot J, Anupama B, Atluri S, Liu J, Khalid U Curr Heart Fail Rep. 2024; 21(5):485-497.

PMID: 39042238 DOI: 10.1007/s11897-024-00677-7.

Splenic infarction: an uncommon yet significant complication in COVID-19 patients - a case series report and literature review.

Pitliya A, Patel M, Batra V, Agrawal B, Kancherla N, Yadav K Infez Med. 2023; 31(4):560-569.

PMID: 38075427 PMC: 10705853. DOI: 10.53854/liim-3104-15.

Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated.

dAlmeida S, Markovic S, Hermann P, Bracht H, Peifer J, Ettrich T Hum Vaccin Immunother. 2023; 19(2):2252239.

PMID: 37655367 PMC: 10478733. DOI: 10.1080/21645515.2023.2252239.

The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study.

Tessema A, Mengiste Z, Hundie T, Yosef H, Huluka D, Seyoum A BMC Pulm Med. 2023; 23(1):85.

PMID: 36915064 PMC: 10010242. DOI: 10.1186/s12890-023-02375-x.

References

Rico-Mesa J, White A, Anderson A . Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020; 22(5):31. PMC: 7154066. DOI: 10.1007/s11886-020-01291-4. View

Lin L, Lu L, Cao W, Li T . Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1):727-732. PMC: 7170333. DOI: 10.1080/22221751.2020.1746199. View

Thachil J . The versatile heparin in COVID-19. J Thromb Haemost. 2020; 18(5):1020-1022. PMC: 9906146. DOI: 10.1111/jth.14821. View

Iba T, Di Nisio M, Levy J, Kitamura N, Thachil J . New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017; 7(9):e017046. PMC: 5623518. DOI: 10.1136/bmjopen-2017-017046. View

Cui S, Chen S, Li X, Liu S, Wang F . Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6):1421-1424. PMC: 7262324. DOI: 10.1111/jth.14830. View

Uthman I, Gharavi A . Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002; 31(4):256-63. DOI: 10.1053/sarh.2002.28303. View

Esmon C . Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2013; 111(4):625-33. DOI: 10.1160/TH13-09-0730. View

Li T, Lu H, Zhang W . Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):687-690. PMC: 7103696. DOI: 10.1080/22221751.2020.1741327. View

Levi M, van der Poll T . Coagulation and sepsis. Thromb Res. 2016; 149:38-44. DOI: 10.1016/j.thromres.2016.11.007. View

10.

Giannis D, Ziogas I, Gianni P . Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127:104362. PMC: 7195278. DOI: 10.1016/j.jcv.2020.104362. View

11.

Ji H, Zhao R, Matalon S, Matthay M . Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020; 100(3):1065-1075. PMC: 7191627. DOI: 10.1152/physrev.00013.2020. View

12.

Yin S, Huang M, Li D, Tang N . Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020; 51(4):1107-1110. PMC: 7124128. DOI: 10.1007/s11239-020-02105-8. View

13.

Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-147. PMC: 7146714. DOI: 10.1016/j.thromres.2020.04.013. View

14.

Bikdeli B, Madhavan M, Jimenez D, Chuich T, Dreyfus I, Driggin E . COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):2950-2973. PMC: 7164881. DOI: 10.1016/j.jacc.2020.04.031. View

15.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-1099. PMC: 9906401. DOI: 10.1111/jth.14817. View

16.

Campbell C, Kahwash R . Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?. Circulation. 2020; 141(22):1739-1741. DOI: 10.1161/CIRCULATIONAHA.120.047419. View

17.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W . Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17):e38. PMC: 7161262. DOI: 10.1056/NEJMc2007575. View

18.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

19.

Poterucha T, Libby P, Goldhaber S . More than an anticoagulant: Do heparins have direct anti-inflammatory effects?. Thromb Haemost. 2016; 117(3):437-444. DOI: 10.1160/TH16-08-0620. View

20.

Iba T, Levy J, Warkentin T, Thachil J, van der Poll T, Levi M . Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019; 17(11):1989-1994. DOI: 10.1111/jth.14578. View